LMNL News and Press, Liminal Biosciences Inc From 06/07/21

Gainers: Ra Medical Systems RMED +54%, Liminal BioSciences LMNL +42%, Atossa Therapeutics (ATOS) +27%, Bionano Genomics BNGO +20%, Clover Health Investments (CLOV) +16%.Losers: Cabaletta Bio (CABA) -10%, MacroGenics (MGNX) -8%, Purple Bio...

A couple of M&A deals highlight Monday U.S. premarket news stream, with deals for U.S. Concrete (USCR) and Macquarie Infrastructure (MIC). At the same time, traders are searching for the next AMC (AMC) ... have they found it in RA Medical Systems (RMED)?Meanwhile, an FDA approval has spar...

Ra Medical Systems (RMED) +56%.Liminal BioSciences (LMNL) +42%.NextDecade Corporation (NEXT) +30%.U.S. Concrete (USCR) +28% as Vulcan Materials buys the Company in $1.3B deal.QTS Realty Trust (QTS) +20% on being acquired by Blackstone funds for $78/share.ChromaDex Corporation (CDXC)...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back to the start of another busy week of trading, investors! We’re kicking off the week with a look at the biggest pre-market stock movers for Monday! Source: f11photo/Shutterstock.com But before we ...

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM) Canada NewsWire LAVAL, QC and CAMBRIDGE, England , June 4, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Co...

Liminal BioSciences ([[LMNL]] -3.1%) announces that the U.S. FDA has approved Ryplazim for the treatment of patients with plasminogen deficiency type 1.The efficacy of the drug in pediatric and adult patients with plasminogen deficiency type 1 was evaluated in a single-arm, open-lab...

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh) Canada NewsWire LAVAL, QC and CAMBRIDGE, England , June 4, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal...

Liminal BioSciences ([[LMNL]] +1.7%) slipped last week after the company ditched its plans to advance fezagepras in Phase 2 and phase 2a/2b clinical studies targeting Idiopathic Pulmonary Fibrosis ((IPF)) and Hypertriglyceridemia ((HTG)), respectively.Piper Sandler analyst Yasmeen Rahimi...

Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers

Liminal BioSciences (LMNL) announces that it has decided to stop its plans to move fezagepras into a Phase II study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, following interim pharmacokinetic ("PK") results.Shares down nearly 12% post market....